Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Maternal and Infant Monitoring for Evidence of Toxicity Related to Tenofovir Exposure: The Bone and Kidney Health Substudy of the IMPAACT 1077 PROMISE Protocol (Promoting Maternal and Infant Survival Everywhere)

Next Previous
Search
Trial Profile

Maternal and Infant Monitoring for Evidence of Toxicity Related to Tenofovir Exposure: The Bone and Kidney Health Substudy of the IMPAACT 1077 PROMISE Protocol (Promoting Maternal and Infant Survival Everywhere)

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 26 Apr 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tenofovir disoproxil fumarate (Primary)
  • Indications HIV infections
  • Focus Pharmacodynamics; Pharmacokinetics
  • Acronyms IMPAACT PROMISE 1077BF; PROMISE

Most Recent Events

  • 06 Mar 2024 Results of nested case-control postpartum substudy (n=93) assessing the association of vertical HIV-1 transmission with HIV VL in plasma and BM, and with tenofovir (TFV) drug levels concentrations, presented at the 31st Conference on Retroviruses and Opportunistic Infections 2024.
  • 15 May 2023 Results from P1084s substudy (n=400 ) assessing Bone and renal health in infants with or without breastmilk exposure to tenofovir-based maternal antiretroviral treatment , published in the JAIDS
  • 16 Feb 2022 Results assessing outcomes in a subset of mother-infant (MI) pairs randomized to either maternal TDF-based ART [TDF/ FTC+LPV/r] (mART) or infant nevirapine prophylaxis [no maternal ART] (iNVP) during breastfeeding as part of the IMPAACT PROMISE study, presented at the 29th Conference on Retroviruses and Opportunistic Infections.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top